{Reference Type}: Systematic Review
{Title}: Menstrual Cycle Hormone Relaxin and ACL Injuries in Female Athletes: A Systematic Review.
{Author}: Parker EA;Duchman KR;Meyer AM;Wolf BR;Westermann RW;
{Journal}: Iowa Orthop J
{Volume}: 44
{Issue}: 1
{Year}: 2024
暂无{Abstract}: <B>UNASSIGNED: </B>Female athletes are at increased risk for anterior cruciate ligament (ACL) injuries. The influence of hormonal variation on female ACL injury risk remains ill-defined. Recent data suggests that the collagen-degrading menstrual hormone relaxin may cyclically impact female ACL tissue quality. This review aims to identify any correlation between menstrual relaxin peaks and rates of female ACL injury.<BR><B>UNASSIGNED: </B>A systematic review was performed, utilizing the MEDLINE, EMBASE, and CINAHL databases. Included studies had to directly address relaxin/female ACL interactions. The primary outcome variable was relaxin proteolysis of the ACL, at cellular, tissue, joint, and whole-organism levels. The secondary outcome variable was any discussed method of moderating relaxin levels, and the clinical results if available.<BR><B>UNASSIGNED: </B>AllThe numerous relaxin receptors on female ACLs upregulate local collagenolysis and suppress local collagen production. Peak serum relaxin concentrations (SRC) occur during menstrual cycle days 21-24; a time phase associated with greater risk of ACL injury. Oral contraceptives (OCPs) reduce SRC, with a potential ACLprotective effect.<BR><B>UNASSIGNED: </B>A reasonable correlative and plausible causative relationship exists between peak relaxin levels and increased risk of ACL injury in females, and further investigation is warranted. Level of Evidence: III.